United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,127,700.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $313.25, for a total value of $1,127,700.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $40,722.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Down 1.6 %

Shares of UTHR stock opened at $323.88 on Friday. The business’s fifty day moving average price is $288.86 and its 200 day moving average price is $249.00. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $330.00. The firm has a market capitalization of $14.37 billion, a PE ratio of 15.31, a P/E/G ratio of 1.39 and a beta of 0.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the prior year, the company posted $4.86 earnings per share. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on UTHR. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $310.00 to $321.00 in a research note on Thursday. The Goldman Sachs Group boosted their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer upped their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. upped their price target on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $321.55.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the company. Rise Advisors LLC acquired a new stake in United Therapeutics in the first quarter valued at $32,000. GAMMA Investing LLC acquired a new stake in United Therapeutics in the fourth quarter valued at $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares during the last quarter. Janiczek Wealth Management LLC grew its holdings in United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 84 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.